- Home
- SANG vs FDMT Comparison
SANG vs FDMT Comparison
Compare SANG & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- FDMT
- Stock Information
- Founded
- SANG 1984
- FDMT 2013
- Country
- SANG Canada
- FDMT United States
- Employees
- SANG N/A
- FDMT N/A
- Industry
- SANG Computer Software: Programming Data Processing
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- SANG Technology
- FDMT Health Care
- Exchange
- SANG Nasdaq
- FDMT Nasdaq
- Market Cap
- SANG 189.6M
- FDMT 161.7M
- IPO Year
- SANG 2021
- FDMT 2020
- Fundamental
- Price
- SANG $5.57
- FDMT $3.95
- Analyst Decision
- SANG
- FDMT Buy
- Analyst Count
- SANG 0
- FDMT 10
- Target Price
- SANG N/A
- FDMT $32.33
- AVG Volume (30 Days)
- SANG 8.0K
- FDMT 437.7K
- Earning Date
- SANG 05-08-2025
- FDMT 05-08-2025
- Dividend Yield
- SANG N/A
- FDMT N/A
- EPS Growth
- SANG N/A
- FDMT N/A
- EPS
- SANG N/A
- FDMT N/A
- Revenue
- SANG $238,264,000.00
- FDMT $23,000.00
- Revenue This Year
- SANG N/A
- FDMT $13,097.30
- Revenue Next Year
- SANG $2.91
- FDMT N/A
- P/E Ratio
- SANG N/A
- FDMT N/A
- Revenue Growth
- SANG N/A
- FDMT N/A
- 52 Week Low
- SANG $4.08
- FDMT $2.24
- 52 Week High
- SANG $7.99
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- SANG 51.00
- FDMT 61.35
- Support Level
- SANG $5.42
- FDMT $3.37
- Resistance Level
- SANG $6.00
- FDMT $3.81
- Average True Range (ATR)
- SANG 0.24
- FDMT 0.26
- MACD
- SANG -0.05
- FDMT 0.05
- Stochastic Oscillator
- SANG 27.03
- FDMT 99.46
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.